COVID-19 Pharmacotherapy: Drug Development, Repurposing of Drugs, and the Role of Pharmacogenomics.
| Autor: | Bock R; Stern College for Women, Yeshiva University, New York, NY, USA., Babayeva M; Touro College of Pharmacy, New York, NY, USA., Loewy ZG; Touro College of Pharmacy, New York, NY, USA. Zvi.loewy@touro.edu.; School of Medicine, New York Medical College, Valhalla, NY, USA. Zvi.loewy@touro.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Methods in molecular biology (Clifton, N.J.) [Methods Mol Biol] 2022; Vol. 2547, pp. 187-199. |
| DOI: | 10.1007/978-1-0716-2573-6_8 |
| Abstrakt: | The SARS-CoV-2 virus has been the subject of intense pharmacological research. Various pharmacotherapeutic approaches including antiviral and immunotherapy are being explored. A pandemic, however, cannot depend on the development of new drugs; the time required for conventional drug discovery and development is far too lengthy. As such, repurposing drugs is being used as a viable approach for identifying pharmacological agents for COVID-19 infections. Evaluation of repurposed drug candidates with pharmacogenomic analysis is being used to identify near-term pharmacological remedies for COVID-19. (© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|